Status:
COMPLETED
Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets
Lead Sponsor:
GlaxoSmithKline
Conditions:
Virus Diseases
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Valaciclovir (VACV), the L-valyl ester prodrug of aciclovir (ACV), is extensively converted to ACV and L-valine after oral administration. In subjects with normal renal function, ACV is predominantly ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Japanese subjects with chronic renal failure undergoing hemodialysis regularly three times a week for at least 12 weeks prior to the start of the study.
- Exclusion criteria:
- Subjects with current alcohol dependence.
- Subjects with gastrointestinal dysfunction that may affect drug absorption.
- Subjects who have received an organ transplant (However, subjects with a corneal transplant or any other organ transplant that may not affect the objectives of the study will be eligible for inclusion in this study).
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00343278
Start Date
July 1 2005
End Date
August 1 2005
Last Update
April 14 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.